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1. Introduction:  
The choroid is a highly vascularised layer that plays an important role in normal 
ocular function. It supplies the outer retina with oxygen and nutrients under highly 
regulated blood flow, acts as a heat diffuser that protects the photoreceptors and also 
secretes growth factors (Nickla and Wallman, 2010). The choroid also directly 
modulates the intraocular pressure (IOP) via vasomotor control of blood flow and 
indirectly through its role in uveoscleral outflow. Given the vascular nature of the 
tissue, the choroid’s morphology is mainly determined by the course and branching 
pattern of the ciliary arteries (Bill et al., 1983). It also contains non-vascular smooth 
muscle cells, a network of spindle- or star-shaped cells that are thought to play a role 
in altering the thickness of the choroid under the influence of local mediators and 
intrinsic choroidal neurons that receive input from the sympathetic and 
parasympathetic nervous system (Nickla and Wallman, 2010; Lütjen-Drecoll, 2006)  
Advances in spectral domain optical coherence tomography (SD-OCT) technology 
have enabled the visualisation and reliable measurements of the human choroid 
(Ikuno et al., 2010; Hirata et al., 2011; Ouyang et al., 2011). Estimates of the average 
subfoveal choroidal thickness in the healthy eyes of adult populations (age 18 and 
over) have ranged between 192 and 354 μm dependent upon the age and refractive 
error distribution of the population (Ikuno et al., 2010; Hirata et al., 2011; Ouyang et 
al., 2011). Some topographical variations in the choroidal thickness across the 
posterior pole have also been found, with the choroid consistently reported to be 
thicker superiorly and temporally, compared to nasal and inferior regions (Hirata et 
al., 2011; Ouyang et al., 2011). Recent clinical studies have found changes in ChT to 
be associated with a number of ocular diseases, such as central serous 
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chorioretinopathy (Maruko et al., 2011b), polypoidal choroidal vasculopathy (Koizumi 
et al., 2011), age related macular degeneration (Manjunath et al., 2011), 
inflammatory eye diseases (Maruko et al., 2011a), inherited retinal dystrophies (Yeoh 
et al., 2010), diabetic retinopathy (Esmaeelpour et al., 2011), and glaucoma (Maul et 
al., 2011). Changes in the thickness of the human choroid have also been found 
associated with age (Manjunath et al., 2011) and the presence of refractive error 
(Ikuno et al., 2010; Hirata et al., 2011). Short term changes in human choroidal 
thickness have also been reported, associated with time of the day (Brown et al., 
2009; Chakraborty et al., 2011; Tan et al., 2012), smoking (Sızmaz et al., 2013), 
caffeine intake (Vural et al., 2013) and with imposed retinal image blur (i.e. hyperopic 
and myopic defocus) (Read et al., 2010; Chakraborty et al., 2012; Chakraborty et al., 
2013).  
Additionally, evidence from animal studies suggests that short-term changes in the 
thickness of the choroid associated with retinal image blur are related to longer term 
changes in eye growth and the development of refractive errors (Wallman et al., 
1995). The magnitude of choroidal thickness variations in relation to defocus found in 
humans (Read et al., 2010; Chakraborty et al., 2012; Chakraborty et al., 2013) and 
mammals (Hung et al., 2000) are substantially smaller than those found in avian 
species (Wallman et al., 1995). Furthermore, several non-selective and selective 
(M4) muscarinic antagonists have been found to cause a transient thickening of the 
choroid in chicks (Nickla et al., 2013) or to prevent the choroidal thinning that is 
normally associated with form-deprivation myopia (McBrien et al., 2011). In contrast, 
a number of non-specific muscarinic agonists stimulated eye elongation and 
choroidal thinning in intact chicken eyes (Nickla et al., 2013). 
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Although the exact mechanism underlying reports of short-term changes in choroidal 
thickness is not known, previous studies have revealed a rich autonomic vasoactive 
nerve supply to the choroid involving the activation of sympathetic adrenergic and 
parasympathetic muscarinic receptors (Neuhuber and Schrödl, 2011). 
Parasympathetic nerves derived from the pterygopalatine ganglion, via the facial 
nerve, form a dense perivascular plexus around the choroidal vessels and mediate 
an increase in blood flow by vasodilatation.  These fibres also terminate on non-
vascular smooth muscle cells and modulate their tonus (Nickla and Wallman, 2010; 
Neuhuber and Schrödl, 2011). In addition, the choroid receives innervation from the 
ciliary ganglion, via the oculomotor nerve that terminates on blood vessels and non-
vascular smooth muscle. However, the role of these fibres in the regulation of 
choroidal blood flow in mammals is not well established, compared to birds where 
they comprise the main parasympathetic input to the choroid (Nickla and Wallman, 
2010; Neuhuber and Schrödl, 2011).  A dense sympathetic innervation originates 
from the ipsilateral superior cervical ganglion, its stimulation causes choroidal 
vasoconstriction mainly via activation of α1–adrenergic receptors located in the 
smooth muscle cells of the vessels (Lanigan et al., 1988). Apart from the autonomic 
innervation, the choroid also receives the sensory fibres that arise from the trigeminal 
ganglion via ophthalmic nerve that exert a vasodilatatory influence on choroidal blood 
flow through local effector function-“axon reflex” in addition to the sensory functions 
(Nickla and Wallman, 2010; Neuhuber and Schrödl, 2011).  
The rich autonomic innervation to various choroidal structures suggests a potential 
involvement of the autonomic system in the regulation of choroidal thickness, either 
through modulation of choroidal blood flow, and/or alterations in the tone of non-
vascular smooth muscle (Nickla and Wallman, 2010). 
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We have examined the effects of the modification of the autonomic nervous system 
activity upon choroidal thickness through the use of topical parasympatholytic and 
sympathomimetic agents. This was measured with SD-OCT at 30 and 60 minutes 
after cholinergic blockade or adrenergic stimulation on different days in healthy 
young adults. By investigating ocular biometry after topical adrenergic and 
anticholinergic agent administration, we hoped to improve our understanding of the 
mechanisms regulating the thickness of the choroid in humans. 
 
2. Material and methods  
2.1. Subjects 
Fourteen young healthy subjects (mean age 27.9 ± 4 years) participated in this 
randomized, single-masked, placebo-controlled study. The study and protocol 
conformed to the tenets of the Declaration of Helsinki and was approved by the 
university human research ethics committee. Subjects were recruited primarily from 
the students and staff of the university. Sixty four percent of the participants (n=9) 
were male and 50% were Caucasian (Caucasian n=7, Indian=6, East Asian n=1). 
Written informed consent was obtained from participants after thorough explanation 
of the nature and risks of the experiment before commencement of the study. None 
of the participants had any significant ocular or systemic disease and had no history 
of ocular injury or surgery. 
Before the study, each participant underwent a full eye examination to determine 
their refractive status and to ensure they met the criteria of good ocular health. All 
subjects had normal visual acuity of logMAR 0.00 or better. Their mean spherical 
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equivalent refractive error was -0.62 ± 1.42 DS (range -4.00 to +0.75 DS). The 
majority of participants exhibited low refractive errors (+0.75 to -0.75 DS) with only 2 
subjects with myopic refractive errors > -0.75 DS. No participant exhibited 
anisometropia of greater than 1.00 DS or cylindrical refraction of greater than 1.00 
DC. Two of the participants were soft contact lens wearers, but they ceased lens 
wear one week prior to participation in the experiment and did not wear lenses for the 
duration of their involvement in the experiment. To limit the potential confounding 
influence of ocular diurnal variations upon the results (Chakraborty et al., 2011), all 
three experimental conditions were tested at approximately the same time of day 
between 9 am and 2 pm on different days, in randomized order, for each subject.  
 
Pharmacologic agents 
Only the right eyes were treated with either: one drop of 2% homatropine 
hydrobromide or one drop of 2.5% phenylephrine hydrochloride or placebo 
(consisting of 0.3% hydroxypropyl methylcellulose) over three separate days, with a 
different pharmacological agent tested at each visit in randomized order. 
Homatropine hydrobromide is a non-selective anticholinergic agent that is closely 
related to atropine (although it has shorter lasting mydriatic and cycloplegic effects), 
while phenylephrine is a selective α1-adrenergic agonist. The drug doses were 
chosen based on the dosage that is commonly used in clinical practice, since these 
doses are known to be safe and to have a clinically significant pharmacological effect 
on the iris and ciliary body function. The doses are also predicted to exceed the 
published ED50 values of phenylephrine (Theofilopoulos et al., 1988) and 
homatropine (Smith, 1976).  To prevent contamination of a trial due to the residual 
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action of a previously administered agent, a washout period up to ten times the 
terminal elimination half- life of the drug was chosen (World Health Organization, 
2004). Both drugs used in the study have terminal half-lives ranging from 2.5-3 hours 
and 3.8-4.8 hours for phenylephrine and homatropine respectively (Dart 2004; 
Gambil et al., 1967). Therefore a washout period of at least 48 hours after the use of 
each agent was implemented. Participants were masked to the pharmacological 
agent being used at each testing session. All eye drops were instilled into the inferior 
conjunctival sac, and participants were directed to close their eyes for approximately 
1 minute following drop instillation to limit loss of medication through the nasolacrimal 
drainage system and to maximise ocular drug contact. 
 
2.2. Procedures 
On each of the three testing days, all subjects had a series of ocular measurements 
taken before and 30 and 60 min following the instillation of one drop of the 
pharmaceutical agent. The room lighting was kept at low photoptic levels for all 
subjects throughout the entire protocol (room illuminance was ~ 10 lux). 
The retinal and choroidal thickness measurements were obtained with the SOCT 
Copernicus HR (Optopol Technology S.A. Zawiecie, Poland). The SOCT Copernicus 
HR is a spectral domain optical coherence tomographer that provides high-
resolution, cross-sectional images of the posterior eye. The instrument uses a super-
luminescent diode light source with centre wavelength of 850 nm (bandwidth 100 nm) 
and has an axial resolution of 3 µm and transverse resolution of 12 to 18 µm. The 
Copernicus HR scans the retina and choroid at 52000 A-scans per second. Recent 
studies have shown that this instrument provides reliable measurements of both 
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retinal and choroidal thickness (Wolf-Schnurrbush et al., 2009; Benavente-Pérez et al 
2010). 
Three series of OCT scans (6 mm length “cross” scans that capture a set of 
horizontal and vertical line scans each centred on the fovea; with each series of 
scans consisting of 30 B-Scans, each with 999 A-scans) were collected from the right 
eye of each participant at each measurement session and were later averaged. To 
enhance the signal from the choroid, the “chorioretinal” scanning mode of the 
instrument was used. Only scans with an image quality index (QI) of more than 4 
(mean ± SD was 6.3 ±1.1) were included in analysis to allow reliable detection of the 
RPE and chorioscleral interface in the analysed OCT images. 
Ocular biometrics before and after instillation of each of the three agents were also 
assessed with a non-contact biometer (Lenstar LS 900; Haag Streit AG, Koeniz, 
Switzerland). This instrument is based on the principle of low coherence optical 
reflectometry and it provides accurate and reliable measures of axial length (AL), 
central corneal thickness (CCT), corneal curvature, lens thickness (LT) and anterior 
chamber depth (ACD) along the visual axis in a single measurement procedure 
(Buckhurst et al., 2009; Cruysberg et al., 2010; Holzer et al., 2009). The instrument 
calculates the axial length based upon the distance between the anterior cornea and 
the retinal pigment epithelium. The anterior corneal curvature measures are based 
upon analysis of the image of 32 reference points reflected from the anterior corneal 
surface oriented in 2 circles at approximately the 2.3 and 1.65 mm optical zones.  
Since the Lenstar does not allow control of accommodation when viewing the 
instrument’s internal fixation target, the biometric measurements may potentially be 
influenced by accommodation. Therefore, accommodation control was achieved with 
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a periscope system consisting of a pair of 45° mirrors and trial frame (in order to 
provide the full distance spherical equivalent refractive correction to the fellow eye) 
mounted in front of the Lenstar (Figure 1). The periscope system allowed two 
different stimuli to be presented to the two eyes (the biometer’s internal fixation target 
to the right eye and an external target at 6 m to the left eye) leading to dichoptic 
(simultaneous) presentation of the stimuli and therefore allowing the biometric 
measurements to be captured during relaxed accommodation. Before the 
measurements were carried out, care was taken to ensure the centre of the external 
target (a high-contrast, Maltese cross) was aligned precisely with the centre of the 
instrument’s measurement beam to ensure on axis (foveal) measurements.  
Thus, the fellow eye viewed a free-space target consisting of a Maltese cross placed 
at the eye’s far point (~0 D accommodative demand) through the trial lens, while the 
treated (right) eye saw the biometer’s fixation target. Subjects were instructed to 
keep the Maltese cross target in sharp focus throughout all measurements and to 
report any misalignment between the two targets. Five consecutive measurements 
were collected from each subject at each measurement session and were later 
averaged. 
IOP was also measured at each session using the Ocular Response Analyser 
instrument (ORA; Reichert, Depew, NY). The ORA provides reliable IOP 
measurements: IOPg, which is calibrated against Goldman applanation tonometry 
and IOPcc which takes corneal biomechanical properties into account and has been 
reported to be less affected by corneal properties than other tonometric techniques 
(Luce, 2005). The mean IOPcc was calculated for each subject at each 
measurement session from a total of four readings. 
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2.3. Data analysis 
The retinal and choroidal thickness data obtained from the SOCT Copernicus HR 
were extracted from the OCT images and calculated with a two-step method. In the 
first step, all 30 individual scans along the horizontal and vertical scan lines in each 
series of scans were aligned to provide average horizontal and vertical B-scan 
images with reduced speckle noise and increased visibility of the retinal layers and 
the chorioscleral interface (Alonso-Caneiro et al., 2011). In the second step, an 
experienced masked observer manually segmented the average B-scan images (3 
horizontal and 3 vertical images at each measurement session) to derive retinal and 
choroidal thickness. The observer selected 16 points along three boundaries in each 
OCT image: the inner boundary of the inner limiting membrane (ILM), the outer 
boundary of the RPE and the inner border of the chorioscleral interface across the 6 
mm length of each average image and the software automatically fitted a smooth 
function (spline fit) to these points. The observer also manually selected the center of 
the fovea on each average OCT scan. Since the transverse resolution of OCT 
images is influenced by AL (Odell et al., 2011), the transverse scale of the images 
was adjusted based upon the participant’s AL obtained with the Lenstar (Lenstar LS 
900; Haag Streit AG) using an approach similar to that described by Wagner-
Schuman et al. (2011). 
Based on the manual segmentation, the average foveal retinal thickness (distance 
between the ILM and the RPE at foveal centre) as well as the average subfoveal and 
parafoveal ChT (distance between the outer boundary of the RPE and the inner 
boundary of the chorioscleral interface, in nasal, superior, temporal and inferior 
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quadrants, extending to 1.5 mm from the fovea average at 0.5 mm intervals) were 
calculated at each measurement session. The individual sectors were referred to as 
the “average subfoveal choroidal thickness” (for the thickness at the center of the 
fovea), nasal, superior, temporal and inferior parafoveal thickness (for the average 
ChT from 0.5 mm away from foveal center to 1.5 mm from the foveal center). Figure 
2 illustrates an example of an average OCT image from a representative subject, 
along with an overview of the retinal and choroidal segmentation and analysis 
procedure used in the study. 
Following data collection, the average of all the biometric parameters (AL, CCT, 
corneal curvature, ACD, LT, RT, subfoveal ChT and parafoveal ChT) and IOP for 
each participant at each measurement session were calculated. The Kolmogorov–
Smirnov test revealed that data from all variables did not depart significantly from a 
normally distributed sample (p> 0.05). A repeated-measures analysis of variance 
(ANOVA) with two within-subject factors (time and drug) was carried out for each of 
the measured variables to determine the significance of changes in each of the 
ocular parameters after instillation of the pharmaceutical agents. Bonferroni corrected 
pairwise comparisons were used to examine individual differences for any variables 
with significant within–subject effects and interactions. Additionally, for the parafoveal 
choroidal thickness data, two additional within-subject factors (parafoveal region [0.5 
mm, 1 mm, 1.5 mm from the fovea center] and quadrant [temporal, nasal, superior 
and inferior]) were included in the ANOVA. 
To provide an assessment of the within-session precision of each of the ocular 
parameters measured, the within-session SD and coefficient of variation (i.e., the 
within-session SD divided by the mean, expressed as a percentage) of the repeated 
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measures for each variable collected at each session were calculated as described 
by Bland and Altman (1999). The intraclass correlation coefficient (ICC) was also 
calculated for each of the ocular parameters. The ICC is an index of measurement 
reliability that ranges from 0 to 1, with values of the ICC> 0.75 having been 
suggested to represent excellent measurement reliability; ICC ≥0.4 represents good 
reliability and ICC< 0.4 to be poor (Portney and Watkins, 2008).  
 
3. Results 
3.1. Within-session repeatability 
The within-session SD and coefficient of variation generally indicated highly precise 
measures for each of the ocular measurements. The within-session SD ranged from 
0.005-0.02 mm for ocular biometrics (AL, CCT, ACD and LT), 0.002-0.012 mm for 
subfoveal and parafoveal ChT, 0.003 mm for RT, 0.169 D for corneal curvature, and 
1.15 mmHg for IOPcc. ICC analysis suggested “excellent” reliability for all variables 
(ICC > 0.90 for all variables). Table 1 illustrates the average within-session variability 
for each of the ocular variables across all measurement sessions. 
 
3.2. Subfoveal choroidal thickness 
Repeated measures ANOVA demonstrated a significant effect of drug, and drug by 
time interaction for the change in subfoveal choroidal thickness from baseline (both 
p<0.0001). Table 2 presents the subfoveal choroidal thickness results for all subjects. 
The instillation of 2% homatropine resulted in a small but significant increase in 
subfoveal ChT (mean change of 7 ± 3 μm, p<0.0001 and 14 ± 2 μm, p< 0.0001) after 
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30 and 60 minutes respectively (Figure 3). Administration of 2.5% phenylephrine 
produced a small decrease in ChT with a mean change of -1 ± 2 μm after 30 min that 
was not statistically significant (p=0.6) and a mean change of -2 ± 2 μm after 60 min 
that bordered on statistical significance (p=0.053). No significant changes in the 
subfoveal ChT from the baseline were found with the placebo at any examination 
points (mean change 0 ± 1 μm and 0 ± 0 μm for 30 and 60 minutes respectively; 
p>0.05). There was also no significant difference between the baseline subfoveal 
ChT measurements (prior to drug instillation) for any of the three conditions tested on 
different days (mean baseline ChT were 343 ± 8 μm, 343 ± 8 μm and 344 ± 8 μm for 
the sessions for 2% homatropine, 2.5% phenylephrine and placebo respectively). 
 
3.3. Parafoveal choroidal thickness 
Table 3 shows the mean changes in the parafoveal choroidal thickness for the four 
(temporal, nasal, superior and inferior) quadrants in 0.5 mm regions located 0.5, 1 
and 1.5 mm from the center of the fovea. Repeated measures ANOVA revealed the 
parafoveal choroid exhibited a similar increase in thickness as that observed in the 
subfoveal choroid with time across all regions after 2% homatropine administration 
(drug by time interaction p< 0.001). Figure 4 shows the mean choroidal thickness 
changes observed in the different parafoveal regions (averaged across all quadrants) 
at 30 and 60 minutes post-instillation.  
Overall, there was a very small decrease in choroidal thickness 30 and 60 minutes 
after administration of 2.5% phenylephrine in all parafoveal regions; however the 
changes were not statistically significant (p> 0.05). Similarly, there was no statistically 
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significant change in parafoveal choroidal thickness after placebo instillation at the 30 
and 60 minutes post-instillation measurements (p> 0.05 for all comparisons).  
 
3.4. Retinal Thickness 
Table 2 shows the mean change in foveal retinal thickness (RT) from baseline for the 
three experimental conditions. On average, retinal thickness at the fovea did not 
change in response to either drug (average RT change was <1 μm, p>0.05 for drug) 
and there were no significant drug by time interactions detected (p > 0.05). 
 
3.5. Ocular Biometry 
Details of the mean ocular biometric changes following use of the three different 
drugs are illustrated in Table 2. On average, none of the anterior eye biometric 
measures (AL, CCT, corneal curvature, ACD, and LT) exhibited significant changes 
after instillation of 2.5% phenylephrine or placebo at both 30 and 60 minutes (p > 
0.05 for all comparisons). In contrast, sixty minutes after administration of 2% 
homatropine the axial length (AL) was significantly shorter (mean change, -6 ± 6 μm; 
p = 0.001, drug by time interaction).  The anterior structures of the eye also 
demonstrated significant changes after homatropine instillation, with anterior 
chamber depth (ACD) deepening (mean change 41 ± 25 μm; and 57 ± 28 μm for 30 
and 60 minutes respectively) and the crystalline lens (LT) thinning (mean change -20 
± 23 μm and -25 ± 28 μm). Pairwise comparisons showed these changes were 
significant for ACD and LT at 60 minutes only (p<0.05) (Table 2). IOP did not 
significantly change after the introduction of any of the three pharmacological agents.  
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4. Discussion:  
The results of this study demonstrate that the anticholinergic agent homatropine can 
increase choroidal thickness (7 - 14 µm) in young healthy adults in both foveal and 
parafoveal regions, presumably by modifying choroidal autonomic nervous system 
activity.  To our knowledge, this is the first study to examine the influence of 
homatropine upon choroidal thickness in human subjects.  Although the changes 
found were of small magnitude, they highlight the importance of muscarinic 
mechanisms in the regulation of choroidal thickness in human subjects.   
 
The exact mechanism driving these changes is unclear; however, alterations in the 
tone of choroidal non-vascular smooth muscle or changes in choroidal blood flow 
have been suggested as two likely causes of choroidal thickening after administration 
of antimuscarinic drugs in animals (Nickla and Wallman, 2010). Evidence of 
contraction of choroidal non-vascular smooth muscle in response to increased 
parasympathetic stimulation (Meriney and Pilar 1987), and the recent finding of 
choroidal thickening following double parasympathectomy in chicks (Nickla and 
Schrödl 2012), suggests an involvement of parasympathetic innervation and non-
vascular smooth muscle in the choroidal thickening response. These findings support 
a potential role of non-vascular smooth muscle in the choroidal thickness changes 
that we have observed with homatropine in humans, whose choroidal non-vascular 
smooth muscle also has parasympathetic innervation (Nickla and Wallman, 2010).   
In contrast, it is generally accepted that acetylcholine (ACh) released from 
parasympathetic cholinergic nerves is a powerful dilator of vascular beds that is 
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primarily dependent upon the release of endothelial nitric oxide  (Toda and Nakanishi 
-Toda, 2007), which would predict a vasoconstriction (and hence a possible thinning 
of the choroid) in response to anticholinergic agents.  However, there is evidence 
from animal studies that anticholinergic drugs such as atropine cause a vasodilation 
response in ocular blood vessels, potentially through their action on pre-junctional 
muscarinic receptors, thus increasing the release of neural nitric oxide (Ayajiki et al 
2000). Therefore, it is possible that the mechanism involved in choroidal thickening 
observed in our study could also involve the presynaptic inhibition of muscarinic 
receptors by homatropine, resulting in increased neural NO release, and subsequent 
relaxation of smooth muscle.    
 
In animal studies, choroidal thickness and ocular growth changes have been shown 
to be influenced by non-selective, partially selective or highly selective  muscarinic 
antagonists (i.e., atropine, pirenzepine, himbaicine, MT3, MT7) implicating 
muscarinic involvement in eye growth and myopia control (Arumugam and McBrien, 
2012; Luft et al., 2003; Diether et al., 2007).  Results from human clinical trials also 
indirectly support this hypothesis, with outcomes demonstrating that daily 
administration of the non-selective muscarinic antagonist 1% atropine, reduced the 
progression of myopia by about 60% during the second year of treatment, and 
concentrations as low as 0.01% atropine still reduced eye growth by 50% (Chua et 
al., 2006; Chia et al., 2012). In our study, the change in ChT of the two myopic 
subjects in response to 2% homatropine (14.1 μm ± 3.1 at 60 min) was not 
substantially different to the response of the remaining 12 emmetropic subjects (13.7 
μm ± 3.5 at 60 min). Our study outcomes add to the evidence that the muscarinic 
17 
 
signalling blockage can also influence choroidal thickness in the human eye, at least 
in the short term. Further research is required to understand if there is a relationship 
between these short term choroidal thickness changes in response to anticholinergic 
agents and longer term changes in eye growth and refractive error development. 
The topical administration of 2.5 % phenylephrine caused only a small decrease in 
choroidal thickness that was not statistically significant.  Increased activity of 
sympathetic adrenergic nerves may be predicted to result in choroidal thinning 
predominantly due to the contraction of vascular muscle cells that contain alpha-
adrenergic receptors. However, the exact role of non-vascular smooth muscle cells in 
this process remains unknown.   Previous studies of the effect of phenylephrine on 
the human eye have produced conflicting results, with some authors observing a 
decrease in choroidal thickness in both the treated and fellow eyes after topical 
phenylephrine administration (Kara et al., 2014), whereas others have reported no 
change in choroidal thickness (Bajenova et al., 2012).   Similarly, reports on changes 
in choroidal blood flow as a result of stimulation of the sympathetic system are also 
equivocal with both reductions in ocular blood flow (Lanigan et al., 1988; Takayama 
et al., 2009)  and no change in posterior eye circulation in healthy human subjects 
reported (Takayama et al., 2004; Robinson et al., 1985; Schmetterer et al., 1996)  , In 
our study, the lack of statistically significant changes in choroidal thickness may 
suggest that phenylephrine did not reach the posterior pole at concentrations 
sufficient to induce a direct vasomotor effect. There are reports (Maurice and 
Mishima, 1984; Del Amo and Urtti, 2008) suggesting that topical administration of the 
various mydriatic agents may not reach concentrations necessary to exert an effect 
at the posterior pole. As the findings from human experiments with phenylephrine 
have provided contradictory results, further studies exploring the potential 
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vasoconstrictive effects of adrenergic stimulants on choroidal blood vessels and 
choroidal thickness changes in human eyes may be warranted. 
To our knowledge only one study (Mwanza et al., 2013) has previously examined the 
effect of a muscarinic antagonist on parafoveal choroidal thickness and they reported 
no significant difference in choroidal thickness after administration of 1% tropicamide 
in healthy individuals and glaucoma patients. Contrary to these findings by Mwanza 
et al. (2013), we did find that topical administration of homatropine produced 
increases in both subfoveal and parafoveal choroidal thickness. These differences in 
choroidal responses to antimuscarinic agents may represent a difference in the 
posterior segment bioavailability of these two drugs (Smith, 1976). The mechanism 
by which topically applied drugs can reach the intraocular environment is through 
both a corneal and a conjunctival/scleral penetration route. Penetration across the 
cornea is proposed as the primary pathway by which drugs reach the anterior 
segment after topical administration, whereas the conjunctiva/scleral route is more 
important to allow access into more posterior structures of the uveal tract (Hughes et 
al., 2005). The relative contribution of this route is more important in case of drugs 
that poorly penetrate across the cornea (Heier et al., 2009).  Since tropicamide shows 
a low affinity and quick corneal penetration (Smith, 1976), it is possible that the dose 
of the drug reaching the posterior eye may be too low to induce choroidal thickness 
changes. 
 
Significant changes in choroidal thickness after treatment with 2% homatropine were 
also accompanied by changes in axial length observed 60 minutes after drug 
administration. The magnitude of these changes was relatively small but statistically 
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significant, with an average of 6 μm of decrease in axial length after the muscarinic 
antagonist administration, with the direction of change (shortening) being consistent 
with previous studies in both avian species (Nickla and Schrödl, 2012) and mammals 
(Arumugam and McBrien, 2012). Since the sub-foveal choroid increased in thickness 
by 14 μm and the axial length decreased by 6 μm 60 minutes after homatropine 
instillation, the unaccounted 8 μm may be the result of the biomechanical forces on 
the globe associated with ciliary muscle relaxation and changes in the iris that also 
led to significant deepening of the anterior chamber and lens thinning. Previous 
animal (Nickla and Schrödl, 2012; Lin et al., 1996; Schmid and Wildsoet, 1996) and 
human (Drexler et al., 1997; Cheung et al., 2009) studies have also reported a 
significant variation in the anterior chamber depth (ACD) and lens thickness (LT) 
measurements after the administration of muscarinic antagonists or surgical 
modification of parasympathetic input to the eye, with trends similar to the results 
obtained in our study. Pharmacologic blockade of cholinergic transmission resulted in 
significant enlargement of ACD and thinning of the lens. In our data, the magnitude of 
LT thinning was smaller than ACD deepening, suggesting a possible posterior 
displacement of the lens. 
Natural variations in choroidal thickness over the course of the day, eye diseases or 
topical and systemic medications should be considered as potential confounders in 
any studies reporting choroidal thickness. Previous studies have found that the 
choroid and axial length undergo significant diurnal fluctuations (Stone et al., 2004; 
Brown et al., 2009; Chakraborty et al., 2011). The choroid is typically thickest in the 
evening and thinnest around noon, while AL changes are antiphase to the ChT 
variations. To ensure consistency and minimize any influence from potential diurnal 
variation, we tested all conditions at approximately the same time of the day. 
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Although our study included only health young adult subjects, our findings highlight 
the potential importance of muscarinic mechanisms in the regulation of choroidal 
thickness in humans. Future research, particularly in older subjects with disease 
(who are more likely to be using medications) should consider the potential for topical 
and/or systemic drugs that can influence the muscarinic system, to be potential 
confounders in studies of choroidal thickness.  
5. Conclusions 
Instillation of the anticholinergic agent 2% homatropine resulted in an increase in 
subfoveal and parafoveal choroidal thickness in young healthy adult subjects. 
Therefore the study results provide important insight into the potential role of 
muscarinic mechanisms in transient choroidal thickening in the human eye.  
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Mean Within-
Session Standard 
Deviation 
Mean Coefficient 
of Variation (%) ICC 
AxL (mm) 0.007 0.03 0.998 
CCT (mm) 0.002 0.35 0.998 
ACD (mm) 0.011 0.41 0.998 
LT (mm) 0.014 0.45 0.996 
Subfoveal ChT 
(mm) 0.002 0.78 0.998 
Parafoveal (0.5 
mm) ChT (mm) 0.002 0.84 0.998 
Parafoveal (1.0 
mm) ChT  (mm) 0.003 0.98 0.997 
Parafoveal ChT 
(mm) 0.004 1.65 0.992 
RT (mm) 0.003 1.45 0.996 
Keratometry 
(D) 0.165 0.38 0.987 
IOPcc (mmHg) 1.158 8.32 0.903 
 
Table 1 Summary of within-session repeatability for each of the ocular variables measured at each measurement session. 
 
 
 
 
 
 
 Mean change from baseline  
(Mean ± SD) 
ANOVA 
p value 
Drug
2% Homatropine 2.5% Phenylephrine Placebo Drug Drug by time 
AL(μm) 
30 min 
60 min 
 
-4 ± 6 
-6 ± 6* 
 
2 ± 4 
3 ± 5 
 
2 ± 7 
3 ± 6 
 
0.723 
 
 0.001 
CCT (μm) 
30 min 
60 min 
 
0 ± 2 
-1 ± 4 
 
0 ± 3 
2 ± 5 
 
0 ± 2 
0 ± 2 
 
0.557 
 
0.380 
ACD (μm) 
30 min 
60 min 
 
41 ± 25 
57 ± 28* 
 
14 ± 14 
23 ± 20 
 
-1 ± 9 
-2 ± 9 
 
0.632 
 
0.011 
LT (μm) 
30 min 
60 min 
 
- 20 ± 23 
-25 ± 27* 
 
-2 ± 6 
-4 ± 8 
 
4 ± 10 
5 ± 9 
 
0.549 
 
 0.047 
RT (μm) 
30 min 
60 min 
 
1 ± 3 
1 ± 3 
 
1 ± 2 
1 ± 3 
 
1 ± 4 
0 ± 4 
 
0.235 
 
0.391 
Subfoveal ChT (μm) 
30 min 
60 min 
 
7 ± 3* 
14 ± 2* 
 
-1 ± 2 
-1.5 ± 2 
 
0 ± 1 
0 ± 0 
 
< 0.0001 
 
< 0.0001 
Keratometry (D) 
30 min 
60 min 
0.01 ± 0.21 
0.05 ± 0.22 
0.02 ± 0.19 
0.03 ± 0.21 
0.01 ± 0.15 
0.03 ± 0.18 0.456 0.251 
IOP (mm Hg) 
30 min 
60 min 
 
0 ± 2 
1 ± 1 
 
0 ± 2 
1 ± 1 
 
-1 ± 1 
-1 ± 2 
 
0.485 
 
0.168 
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Table 2 Effects of 2% homatropine, 2.5 % phenylephrine and placebo on the mean change in ocular parameters at 30 and 60 minutes from the baseline. Statistically significant ANOVA main effects 
and interactions (p<0.05) are highlighted in bold. Asterisks indicate significant changes from baseline in the ocular parameter, from the Bonferroni corrected pairwise comparisons (p<0.05).Positive 
values represent an increase in choroidal thickness, while the negative values correspond to a decrease in choroidal thickness.
  
Quadrant 
Region 
(mm) 
Time 
Change from baseline (μm) Mean ± SD 
Drug 
2% Homatropine 2.5% Phenylephrine Placebo 
Temporal 
0.5 30 7 ± 4* 0 ± 1 0 ± 1 
60 14 ± 4* -1 ± 2 0 ± 1 
1.0 30 6 ± 3*  0 ± 2 0 ± 2 
60 14 ± 3*  0 ± 2 0 ± 3 
1.5 30 7 ± 2* -1 ± 1 0 ± 0 
60 13 ± 3* -1 ± 3 -1 ± 4 
Nasal 
0.5 30 7 ± 4* -1 ± 1 0 ± 2 
60 11 ± 4* -1 ± 2 0 ± 1 
1.0 30 7 ± 6* 0 ± 2 -1 ± 2 
60 13 ± *6 -1 ± 2 -1 ± 2 
1.5 30 7 ± 3* 0 ± 2 0 ± 1 
60 13 ± 5*  1 ± 3 -1 ± 2 
Superior 
0.5 30 6 ± 3* -1 ± 1 0 ± 1 
60 13 ± 4* -1 ± 1 0 ± 1 
1.0 30 6 ± 3*  0 ± 2 -1 ± 2 
60 13 ± 2* -1 ± 1. -1 ± 2 
1.5 30 4 ± 3* 0 ± 1 0 ±1 
60 10 ± 3* -1 ± 1 0 ± 2 
Inferior 
0.5 30 7 ± 4* 0 ± 1 0 ± 1 
60 13 ± 4* -1 ± 1 0 ± 1 
1.0 30 5 ± 4* -1 ± 2 1 ± 2 
60 11 ± 3* -1 ± 2 0 ± 1 
1.5 30 5 ± 5* -1 ± 1 1 ± 2 
60 11 ± 5* -1 ± 1 -1 ± 2 
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Table 3 Mean change in parafoveal choroidal thickness from the baseline after 30 and 60 minutes of exposure to three different drugs for four choroidal quadrants within three different regions.. 
Asterisks indicate significant changes from baseline in the ocular parameter, from the Bonferroni corrected pairwise comparisons (p<0.05).Positive values represent an increase in choroidal 
thickness, while the negative values correspond to a decrease in choroidal thickness. 
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Figure captions: 2 
 3 
Figure 1 4 
Schematic diagram of the experimental set-up for ocular biometry measurements 5 
using a periscope system (consisting of a pair of mirrors (M1 and M2), and a 6 
correcting lens) with the Lenstar and a correcting lens that allows ocular biometry to 7 
be measured along the line of sight with relaxed accommodation under binocular 8 
dichoptic fixation. 9 
 10 
Figure 2 11 
Example of a representative average OCT image from one subject (derived from the 12 
average of 30 individual B-Scans), and the analysis procedure performed on the 13 
images captured (i.e. 3 vertical and 3 horizontal average images at each 14 
measurement session) for each subject. Manual segmentation defined the inner 15 
limiting membrane, the outer border of the RPE and inner border of the chorioscleral 16 
interface (white lines) in each image. Retinal thickness was defined as the distance 17 
from the inner limiting membrane and the outer border of the RPE. The subfoveal 18 
and parafoveal choroidal thickness (white continuous and dotted lines in the average 19 
B-scan respectively) were determined as the distance from the RPE to the 20 
chorioscleral interface in each of the manually segmented B-scans. White bars 21 
represent the choroidal thickness measurements at the fovea and at 0.5 mm intervals 22 
up to 1.5 mm. 23 
 24 
 25 
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 1 
Figure 3 2 
Mean change from baseline in subfoveal ChT at 30 and 60 min after drug instillation. 3 
Pairwise comparison revealed a significant increase in choroidal thickness at 30 and 4 
60 minutes after 2% homatropine administration (asterisk shows p < 0.0001) when 5 
compared to 2.5% phenylephrine and placebo (both p> 0.05). Error bars represent ± 6 
SD. 7 
 8 
Figure 4 9 
Mean change from baseline in parafoveal ChT 30 and 60 min after drug instillation 10 
for average of 0°, 90°, 180° and 270° measurement meridians. Error bars represent ± 11 
SD. The values under each of the bars on the x axis represent the distance in mm 12 
from the foveal center where each of the parafoveal choroidal thickness 13 
measurements were taken.  14 
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